Chugai Pharmaceutical (OTCMKTS:CHGCY – Get Free Report) was upgraded by equities research analysts at UBS Group to a “strong-buy” rating in a research note issued to investors on Tuesday,Zacks.com reports. Chugai Pharmaceutical Trading Down 2.1%Chugai Pharmaceutical stock opened at $27.52 on Tuesday. Chugai Pharmaceutical has a 1-year low of $19.50 and a 1-year high of $31.26. Get Chugai Pharmaceutical alerts:Chugai Pharmaceutical Company Profile(Get Free Report)Chugai Pharmaceutical Co, Ltd. is a Japan-based biopharmaceutical company headquartered in Tokyo that focuses on the discovery, development, manufacture and marketing of prescription medicines. Read MoreReceive News & Ratings for Chugai Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chugai Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.